Alzheimer’s Association: Part the Cloud Translational Research: Phase 1 and Phase 2 Clinical Studies

If you are interested in this opportunity, please contact Carole King at carole.king@med.usc.edu.

• LOI due August 6, 2025
• Amount up to $1,000,000 (including 10% indirects)
• Project period up to three years

This new grant mechanism aims to fill the gap in Alzheimer’s disease and related dementia clinical trials for advancing potential therapeutics by providing support for early phase studies (Phase 1 and Phase 2).

This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with symptomatic or symptomatic Alzheimer’s and related dementia, including single and multiple dose studies to establish safety, brain penetration and/or target engagement and proof of mechanism in preparation for larger proof of concept trials.

In addition, proposals may be considered that are proof of concept to validate biological marker(s) of disease progression in a clinical trial environment.